vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and Tempus AI, Inc. (TEM). Click either name above to swap in a different company.
Tempus AI, Inc. is the larger business by last-quarter revenue ($367.2M vs $177.4M, roughly 2.1× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -14.8%, a 16.4% gap on every dollar of revenue. On growth, Tempus AI, Inc. posted the faster year-over-year revenue change (83.0% vs 5.0%). Over the past eight quarters, Tempus AI, Inc.'s revenue compounded faster (58.7% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Tempus AI, Inc. is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. It was established by Lefkofsky soon after his wife was diagnosed with breast cancer. Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, for oncology, cardiology, radiology, and depression. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM."
PCRX vs TEM — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $367.2M |
| Net Profit | $2.9M | $-54.2M |
| Gross Margin | — | — |
| Operating Margin | 3.9% | -16.7% |
| Net Margin | 1.6% | -14.8% |
| Revenue YoY | 5.0% | 83.0% |
| Net Profit YoY | — | -316.2% |
| EPS (diluted) | $0.07 | $-0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $367.2M | ||
| Q3 25 | $179.5M | $334.2M | ||
| Q2 25 | $181.1M | $314.6M | ||
| Q1 25 | $168.9M | $255.7M | ||
| Q4 24 | $187.3M | $200.7M | ||
| Q3 24 | $168.6M | $180.9M | ||
| Q2 24 | $178.0M | $166.0M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $-54.2M | ||
| Q3 25 | $5.4M | $-80.0M | ||
| Q2 25 | $-4.8M | $-42.8M | ||
| Q1 25 | $4.8M | $-68.0M | ||
| Q4 24 | — | $-13.0M | ||
| Q3 24 | $-143.5M | $-75.8M | ||
| Q2 24 | $18.9M | $-552.2M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | -16.7% | ||
| Q3 25 | 3.5% | -18.3% | ||
| Q2 25 | 4.7% | -19.6% | ||
| Q1 25 | 1.2% | -26.9% | ||
| Q4 24 | 13.2% | -25.3% | ||
| Q3 24 | -82.8% | -29.6% | ||
| Q2 24 | 15.9% | -321.4% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | -14.8% | ||
| Q3 25 | 3.0% | -23.9% | ||
| Q2 25 | -2.7% | -13.6% | ||
| Q1 25 | 2.8% | -26.6% | ||
| Q4 24 | — | -6.5% | ||
| Q3 24 | -85.1% | -41.9% | ||
| Q2 24 | 10.6% | -332.7% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $-0.30 | ||
| Q3 25 | $0.12 | $-0.46 | ||
| Q2 25 | $-0.11 | $-0.25 | ||
| Q1 25 | $0.10 | $-0.40 | ||
| Q4 24 | $0.38 | $2.56 | ||
| Q3 24 | $-3.11 | $-0.46 | ||
| Q2 24 | $0.39 | $-6.86 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $604.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $653.9M | $491.3M |
| Total Assets | $1.2B | $2.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $604.8M | ||
| Q3 25 | $246.3M | $655.9M | ||
| Q2 25 | $445.9M | $186.3M | ||
| Q1 25 | $493.6M | $151.6M | ||
| Q4 24 | $484.6M | $341.0M | ||
| Q3 24 | $453.8M | $388.0M | ||
| Q2 24 | $404.2M | $478.8M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $491.3M | ||
| Q3 25 | $727.2M | $507.8M | ||
| Q2 25 | $757.8M | $309.6M | ||
| Q1 25 | $798.5M | $326.2M | ||
| Q4 24 | $778.3M | $56.3M | ||
| Q3 24 | $749.6M | $53.7M | ||
| Q2 24 | $879.3M | $98.3M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $2.3B | ||
| Q3 25 | $1.3B | $2.3B | ||
| Q2 25 | $1.5B | $1.6B | ||
| Q1 25 | $1.6B | $1.5B | ||
| Q4 24 | $1.6B | $926.1M | ||
| Q3 24 | $1.5B | $971.7M | ||
| Q2 24 | $1.6B | $864.6M |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-36.8M |
| Free Cash FlowOCF − Capex | — | $-41.5M |
| FCF MarginFCF / Revenue | — | -11.3% |
| Capex IntensityCapex / Revenue | — | 1.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-239.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $-36.8M | ||
| Q3 25 | $60.8M | $-119.8M | ||
| Q2 25 | $12.0M | $44.2M | ||
| Q1 25 | $35.5M | $-105.6M | ||
| Q4 24 | $33.1M | — | ||
| Q3 24 | $53.9M | $48.7M | ||
| Q2 24 | $53.2M | $-97.1M |
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $-41.5M | ||
| Q3 25 | $57.0M | $-126.5M | ||
| Q2 25 | $9.3M | $36.6M | ||
| Q1 25 | $26.9M | $-107.7M | ||
| Q4 24 | $31.0M | — | ||
| Q3 24 | $49.8M | $48.6M | ||
| Q2 24 | $51.6M | $-105.1M |
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | -11.3% | ||
| Q3 25 | 31.7% | -37.9% | ||
| Q2 25 | 5.1% | 11.6% | ||
| Q1 25 | 15.9% | -42.1% | ||
| Q4 24 | 16.6% | — | ||
| Q3 24 | 29.6% | 26.9% | ||
| Q2 24 | 29.0% | -63.3% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 1.3% | ||
| Q3 25 | 2.2% | 2.0% | ||
| Q2 25 | 1.5% | 2.4% | ||
| Q1 25 | 5.1% | 0.8% | ||
| Q4 24 | 1.1% | — | ||
| Q3 24 | 2.4% | 0.0% | ||
| Q2 24 | 0.9% | 4.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
TEM
Segment breakdown not available.
